Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.03
SHPG's Cash to Debt is ranked lower than
98% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. SHPG: 0.03 )
Ranked among companies with meaningful Cash to Debt only.
SHPG' s 10-Year Cash to Debt Range
Min: 0.03  Med: 1.35 Max: No Debt
Current: 0.03
Equity to Asset 0.54
SHPG's Equity to Asset is ranked lower than
65% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SHPG: 0.54 )
Ranked among companies with meaningful Equity to Asset only.
SHPG' s 10-Year Equity to Asset Range
Min: 0.25  Med: 0.63 Max: 0.85
Current: 0.54
0.25
0.85
Interest Coverage 55.13
SHPG's Interest Coverage is ranked lower than
85% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SHPG: 55.13 )
Ranked among companies with meaningful Interest Coverage only.
SHPG' s 10-Year Interest Coverage Range
Min: 2.96  Med: 22.62 Max: 55.13
Current: 55.13
2.96
55.13
F-Score: 6
Z-Score: 4.70
M-Score: -3.02
WACC vs ROIC
11.87%
18.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 26.64
SHPG's Operating margin (%) is ranked higher than
90% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. SHPG: 26.64 )
Ranked among companies with meaningful Operating margin (%) only.
SHPG' s 10-Year Operating margin (%) Range
Min: -56.61  Med: 20.62 Max: 35.13
Current: 26.64
-56.61
35.13
Net-margin (%) 51.71
SHPG's Net-margin (%) is ranked higher than
96% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. SHPG: 51.71 )
Ranked among companies with meaningful Net-margin (%) only.
SHPG' s 10-Year Net-margin (%) Range
Min: -59.59  Med: 15.49 Max: 56.55
Current: 51.71
-59.59
56.55
ROE (%) 41.15
SHPG's ROE (%) is ranked higher than
97% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. SHPG: 41.15 )
Ranked among companies with meaningful ROE (%) only.
SHPG' s 10-Year ROE (%) Range
Min: -90.17  Med: 14.54 Max: 49.38
Current: 41.15
-90.17
49.38
ROA (%) 22.75
SHPG's ROA (%) is ranked higher than
96% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. SHPG: 22.75 )
Ranked among companies with meaningful ROA (%) only.
SHPG' s 10-Year ROA (%) Range
Min: -37.5  Med: 8.65 Max: 31.55
Current: 22.75
-37.5
31.55
ROC (Joel Greenblatt) (%) 299.88
SHPG's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. SHPG: 299.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SHPG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -396.76  Med: 103.03 Max: 345.44
Current: 299.88
-396.76
345.44
Revenue Growth (3Y)(%) 12.40
SHPG's Revenue Growth (3Y)(%) is ranked higher than
69% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. SHPG: 12.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SHPG' s 10-Year Revenue Growth (3Y)(%) Range
Min: -0.7  Med: 12.70 Max: 26.8
Current: 12.4
-0.7
26.8
EBITDA Growth (3Y)(%) 38.70
SHPG's EBITDA Growth (3Y)(%) is ranked higher than
88% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. SHPG: 38.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SHPG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -1.4  Med: 22.80 Max: 38.7
Current: 38.7
-1.4
38.7
EPS Growth (3Y)(%) 56.30
SHPG's EPS Growth (3Y)(%) is ranked higher than
94% of the 420 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. SHPG: 56.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SHPG' s 10-Year EPS Growth (3Y)(%) Range
Min: -6.9  Med: 31.80 Max: 62.8
Current: 56.3
-6.9
62.8
» SHPG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

SHPG Guru Trades in Q3 2014

Paul Singer 107,800 sh (New)
Mario Gabelli 37,850 sh (New)
Jeremy Grantham 1,845,359 sh (New)
Richard Perry 695,800 sh (New)
Daniel Loeb 750,000 sh (New)
David Tepper 185,944 sh (New)
First Eagle Investment 15,000 sh (New)
Louis Moore Bacon 45,300 sh (+806.00%)
John Paulson 9,046,000 sh (+168.70%)
Murray Stahl 6,000 sh (unchged)
Ken Fisher 2,827 sh (-39.56%)
Jim Simons 320,312 sh (-52.59%)
Eric Mindich 76,781 sh (-69.41%)
» More
Q4 2014

SHPG Guru Trades in Q4 2014

Andreas Halvorsen 529,784 sh (New)
Pioneer Investments 110,458 sh (New)
Leon Cooperman 473,237 sh (New)
First Eagle Investment 82,986 sh (+453.24%)
Ken Fisher 14,594 sh (+416.24%)
Louis Moore Bacon 59,292 sh (+30.89%)
Murray Stahl 6,000 sh (unchged)
David Tepper Sold Out
Richard Perry Sold Out
Paul Singer Sold Out
Jeremy Grantham Sold Out
Eric Mindich Sold Out
Jim Simons Sold Out
John Paulson 8,328,304 sh (-7.93%)
Daniel Loeb 500,000 sh (-33.33%)
Mario Gabelli 16,225 sh (-57.13%)
» More
Q1 2015

SHPG Guru Trades in Q1 2015

Jim Simons 197,512 sh (New)
Steven Cohen 4,600 sh (New)
First Eagle Investment 294,539 sh (+254.93%)
Leon Cooperman 500,192 sh (+5.70%)
Pioneer Investments 116,323 sh (+5.31%)
Ken Fisher 14,791 sh (+1.35%)
Murray Stahl 6,000 sh (unchged)
John Paulson 8,328,304 sh (unchged)
Mario Gabelli Sold Out
Andreas Halvorsen Sold Out
Daniel Loeb Sold Out
Louis Moore Bacon 20,000 sh (-66.27%)
» More
Q2 2015

SHPG Guru Trades in Q2 2015

Manning & Napier Advisors, Inc 786,159 sh (New)
Ken Fisher 20,161 sh (+36.31%)
Jim Simons 264,812 sh (+34.07%)
Murray Stahl 6,000 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Leon Cooperman 496,192 sh (-0.80%)
John Paulson 7,095,100 sh (-14.81%)
Pioneer Investments 75,972 sh (-34.69%)
First Eagle Investment 4,830 sh (-98.36%)
» More
» Details

Insider Trades

Latest Guru Trades with SHPG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Shire PLC

Manning & Napier's Top 5 New Stock Buys of Q2
Fund manager Manning & Napier purchased 61 new stocks across its portfolios in the second quarter. Read more...
Manning & Napier Invests in Stake in Baidu
In the first decade of the 21st century, Manning & Napier was the only investment manager to beat the S&P500 every year. Read more...
Shire Set To Acquire NPS Pharmaceuticals for $5.2 Billion
Following a number of pharma mergers last year, which included the likes of Actavis and Forest Laboratories, Shire (NASDAQ:SHPG) announced on Jan. 11 that it is acquiring NPS Pharmaceuticals (NASDAQ:NPSP) for $5.2 billion. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 14.60
SHPG's P/E(ttm) is ranked higher than
86% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 36.10 vs. SHPG: 14.60 )
Ranked among companies with meaningful P/E(ttm) only.
SHPG' s 10-Year P/E(ttm) Range
Min: 12.37  Med: 24.27 Max: 74.35
Current: 14.6
12.37
74.35
Forward P/E 54.95
SHPG's Forward P/E is ranked higher than
68% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 22.73 vs. SHPG: 54.95 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 14.40
SHPG's PE(NRI) is ranked higher than
86% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 35.00 vs. SHPG: 14.40 )
Ranked among companies with meaningful PE(NRI) only.
SHPG' s 10-Year PE(NRI) Range
Min: 12.85  Med: 22.64 Max: 106.93
Current: 14.4
12.85
106.93
P/B 5.25
SHPG's P/B is ranked lower than
57% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. SHPG: 5.25 )
Ranked among companies with meaningful P/B only.
SHPG' s 10-Year P/B Range
Min: 2.03  Med: 5.43 Max: 14.23
Current: 5.25
2.03
14.23
P/S 7.50
SHPG's P/S is ranked higher than
60% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.19 vs. SHPG: 7.50 )
Ranked among companies with meaningful P/S only.
SHPG' s 10-Year P/S Range
Min: 2.25  Med: 4.35 Max: 9.37
Current: 7.5
2.25
9.37
PFCF 13.45
SHPG's PFCF is ranked higher than
86% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 39.55 vs. SHPG: 13.45 )
Ranked among companies with meaningful PFCF only.
SHPG' s 10-Year PFCF Range
Min: 10.8  Med: 22.99 Max: 42.14
Current: 13.45
10.8
42.14
POCF 11.29
SHPG's POCF is ranked higher than
88% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. SHPG: 11.29 )
Ranked among companies with meaningful POCF only.
SHPG' s 10-Year POCF Range
Min: 7.59  Med: 16.32 Max: 26.82
Current: 11.29
7.59
26.82
EV-to-EBIT 15.14
SHPG's EV-to-EBIT is ranked higher than
74% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 27.86 vs. SHPG: 15.14 )
Ranked among companies with meaningful EV-to-EBIT only.
SHPG' s 10-Year EV-to-EBIT Range
Min: -14.6  Med: 17.40 Max: 58.7
Current: 15.14
-14.6
58.7
PEG 0.53
SHPG's PEG is ranked higher than
94% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 2.26 vs. SHPG: 0.53 )
Ranked among companies with meaningful PEG only.
SHPG' s 10-Year PEG Range
Min: 0.52  Med: 1.50 Max: 2.28
Current: 0.53
0.52
2.28
Shiller P/E 38.40
SHPG's Shiller P/E is ranked higher than
59% of the 113 Companies
in the Global Biotechnology industry.

( Industry Median: 44.53 vs. SHPG: 38.40 )
Ranked among companies with meaningful Shiller P/E only.
SHPG' s 10-Year Shiller P/E Range
Min: 30.3  Med: 61.13 Max: 143.7
Current: 38.4
30.3
143.7
Current Ratio 0.59
SHPG's Current Ratio is ranked lower than
91% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. SHPG: 0.59 )
Ranked among companies with meaningful Current Ratio only.
SHPG' s 10-Year Current Ratio Range
Min: 0.52  Med: 1.77 Max: 7.43
Current: 0.59
0.52
7.43
Quick Ratio 0.44
SHPG's Quick Ratio is ranked lower than
92% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. SHPG: 0.44 )
Ranked among companies with meaningful Quick Ratio only.
SHPG' s 10-Year Quick Ratio Range
Min: 0.4  Med: 1.54 Max: 7.07
Current: 0.44
0.4
7.07
Days Inventory 224.82
SHPG's Days Inventory is ranked lower than
77% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 120.98 vs. SHPG: 224.82 )
Ranked among companies with meaningful Days Inventory only.
SHPG' s 10-Year Days Inventory Range
Min: 113.05  Med: 177.10 Max: 270.35
Current: 224.82
113.05
270.35
Days Sales Outstanding 64.66
SHPG's Days Sales Outstanding is ranked lower than
52% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. SHPG: 64.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
SHPG' s 10-Year Days Sales Outstanding Range
Min: 47.71  Med: 66.14 Max: 101.67
Current: 64.66
47.71
101.67

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.29
SHPG's Dividend Yield is ranked lower than
91% of the 238 Companies
in the Global Biotechnology industry.

( Industry Median: 1.25 vs. SHPG: 0.29 )
Ranked among companies with meaningful Dividend Yield only.
SHPG' s 10-Year Dividend Yield Range
Min: 0.16  Med: 0.42 Max: 0.7
Current: 0.29
0.16
0.7
Dividend Payout 0.04
SHPG's Dividend Payout is ranked higher than
98% of the 118 Companies
in the Global Biotechnology industry.

( Industry Median: 0.36 vs. SHPG: 0.04 )
Ranked among companies with meaningful Dividend Payout only.
SHPG' s 10-Year Dividend Payout Range
Min: 0.05  Med: 0.26 Max: 1.23
Current: 0.04
0.05
1.23
Dividend growth (3y) 16.00
SHPG's Dividend growth (3y) is ranked higher than
74% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 6.30 vs. SHPG: 16.00 )
Ranked among companies with meaningful Dividend growth (3y) only.
SHPG' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 13.45 Max: 57.9
Current: 16
0
57.9
Yield on cost (5-Year) 0.66
SHPG's Yield on cost (5-Year) is ranked lower than
78% of the 238 Companies
in the Global Biotechnology industry.

( Industry Median: 1.49 vs. SHPG: 0.66 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SHPG' s 10-Year Yield on cost (5-Year) Range
Min: 0.34  Med: 0.90 Max: 1.5
Current: 0.66
0.34
1.5
Share Buyback Rate 0.20
SHPG's Share Buyback Rate is ranked higher than
93% of the 539 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. SHPG: 0.20 )
Ranked among companies with meaningful Share Buyback Rate only.
SHPG' s 10-Year Share Buyback Rate Range
Min: 1.4  Med: -2.60 Max: -28.8
Current: 0.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.66
SHPG's Price/Projected FCF is ranked higher than
81% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. SHPG: 1.66 )
Ranked among companies with meaningful Price/Projected FCF only.
SHPG' s 10-Year Price/Projected FCF Range
Min: 1.12  Med: 1.72 Max: 2.65
Current: 1.66
1.12
2.65
Price/Median PS Value 1.75
SHPG's Price/Median PS Value is ranked lower than
72% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. SHPG: 1.75 )
Ranked among companies with meaningful Price/Median PS Value only.
SHPG' s 10-Year Price/Median PS Value Range
Min: 0.56  Med: 0.98 Max: 2.92
Current: 1.75
0.56
2.92
Price/Peter Lynch Fair Value 0.64
SHPG's Price/Peter Lynch Fair Value is ranked higher than
90% of the 52 Companies
in the Global Biotechnology industry.

( Industry Median: 1.85 vs. SHPG: 0.64 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
SHPG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.61  Med: 1.42 Max: 2.92
Current: 0.64
0.61
2.92
Earnings Yield (Greenblatt) (%) 6.63
SHPG's Earnings Yield (Greenblatt) (%) is ranked higher than
93% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. SHPG: 6.63 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SHPG' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.7  Med: 5.20 Max: 15.7
Current: 6.63
1.7
15.7
Forward Rate of Return (Yacktman) (%) 31.50
SHPG's Forward Rate of Return (Yacktman) (%) is ranked higher than
80% of the 100 Companies
in the Global Biotechnology industry.

( Industry Median: 13.39 vs. SHPG: 31.50 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SHPG' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 1.5  Med: 2.40 Max: 30.2
Current: 31.5
1.5
30.2

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 6,291 7,041 7,549
EPS($) 3.69 4.29 4.81
EPS without NRI($) 3.69 4.29 4.81

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SHP.UK, S7E.Germany, SHPG N.Mexico, SP2.Germany, SHPGF.USA,
Shire PLC was registered in Jersey on 28th January, 2008. It is a specialty biopharmaceutical company that focuses on developing and marketing specialty medicines that address unmet patient needs. The Company unified its business during 2013 by integrating the operations of the Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT) and Regenerative Medicine (RM) business units into a simplified One Shire organization. The Company has four commercial units that focus exclusively on the commercial execution of its In-Line products in the following specialist therapeutic areas: Rare Diseases, Neuroscience, Gastrointestinal (GI) and Internal Medicine. The clinical development, manufacturing and marketing of the Company's products is subject to governmental regulation in the US, the EU and other territories.
» More Articles for SHPG

Headlines

Articles On GuruFocus.com
Undervalued Baxalta Shares Target of Acquisition by Shire Plc Aug 05 2015 
Manning & Napier's Top 5 New Stock Buys of Q2 Jul 09 2015 
Manning & Napier Invests in Stake in Baidu Jul 08 2015 
Invesco European Growth Fund Parts With Two Stakes Jul 01 2015 
Andreas Halvorsen Increases Stake in Esperion Therapeutics Jun 29 2015 
Smart Guru John Paulson Bullish on Actavis Jun 18 2015 
8 Top Healthcare Stocks to Watch May 13 2015 
John Paulson's Stocks Trading at Low P/E May 04 2015 
Shire Reports A Good Quarter Promoted By Drug Sales May 03 2015 
Top Stock Picks Among Companies That Recently Increased Dividends Mar 09 2015 

More From Other Websites
Drugmaker Baxalta in talks to buy Ariad - Bloomberg Aug 28 2015
Baxalta in talks to buy U.S. hematology-oncology specialist - Bloomberg Aug 28 2015
Why I’d Buy Hikma Pharmaceuticals Plc, Hold Shire plc & Sell AstraZeneca plc Aug 28 2015
Why I'd Buy Hikma Pharmaceuticals Plc, Hold Shire plc & Sell AstraZeneca plc Aug 28 2015
Shire Inks Deal with Sanquin to Expand Cinryze Production Aug 26 2015
Could SkyePharma PLC Outperform Shire PLC And Hikma Pharmaceuticals Plc? Aug 26 2015
Could SkyePharma PLC Outperform Shire PLC And Hikma Pharmaceuticals Plc? Aug 26 2015
Shire Falls but Mylan’s Rise Boosts Large-Cap IBB Pharma Subgroup Aug 25 2015
Shire to Attain Enhanced CINRYZE® Manufacturing Flexibility and Capacity Aug 25 2015
SHIRE PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 24 2015
IBB Outperforms XBI: Top 10 Large-Cap Stocks Aug 20 2015
Billionaire Paulson’s Top Healthcare Picks Include Allergan PLC (AGN), Valeant Pharmaceuticals... Aug 20 2015
Regeneron Leads and Shire Dragged the Large-Cap Stocks Aug 19 2015
Benzinga's M&A Chatter for Tuesday August 18, 2015 Aug 18 2015
John Paulson Betting On Healthcare And Consumer Discretionary Stocks Aug 18 2015
Britain's FTSE falters as commodity stocks crumple Aug 18 2015
Britain's FTSE falters as commodity stocks crumple Aug 18 2015
Britain's FTSE falters as commodity stocks crumple Aug 18 2015
Britain's FTSE falters as commodity stocks crumple Aug 18 2015
Britain's FTSE falters as commodity stocks crumple Aug 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK